Orders recover from Q4 low, NWC release supports fantastic FCF Some one-offs weigh on profitability,...
Redeye is encouraged to see a slightly higher-than-expected sales development for US CERAMENT G and ...
Orders -5%, sales +1%, adj. EBITA -7% vs. ABGSCe Some negative one-offs in quarter: system changes, ...
Redeye leaves a comment following today’s announcement that Kristina Torfgård has decided to leave h...
Redeye sees the RPDD and ODD from the FDA as signs that the osteoarthritis programme MIV-711 is movi...
Redeye comments on the decision of NICE not to recommend Pepaxti in the UK, which is not unexpected.
Redeye was hoping for a bit more in terms of top-line growth, but we are encouraged by strong gross ...
- Q1: Clean EBITDA NOK -6m - soft compared to our NOK -1m - Targets updated - more achievable - Esti...
Osäkerheten består i det korta, men de strukturella drivkrafterna består Även om affären fortsatte p...
Fortsatt vikande ARR y/y och q/q… Omsättningen i kvartalet uppgick till 37,3 mkr, vilket motsvarar e...
Lägre andel underkonsulter och en arbetsdag mindre Inledningen av 2024 fortsätter att vara stabil oc...
God tillväxt och fortsatta interna förbättringar i utmanande miljö Bokusgruppen rapporterade en över...
Redeye comments on the change of CEO.
DT’s Q1 earnings were clearly above estimates even though revenue was basically as expected.
There has been a somewhat mixed news flow from Prolight after the close of Q1’24.
Dovre Q1 results included a write-down of EUR 5.8m related to a single renewable energy project.
We note another quarter in which the operations have not yet translated into meaningful sales.
SRV's net sales in Q1 amounted to EUR 167.0m, above our estimate of EUR 152.
Consti's net sales in Q1 amounted to EUR 65.5m, only slightly higher than our estimate (Evli est.
Redeye has interviewed SSH's Interim CEO, Rami Raulas, regarding the Q1 report.
